Introduction
- 1. Alcohol withdrawal syndrome (AWS) is a disease commonly treated in the emergency department, with ~5% of cases leading to delirium tremens.
- 2. In patients with a history of AWS, decreased GABA-A receptor sensitivity to GABA agonists may cause benzodiazepine (BZD) monotherapy to be ineffective.
- 3. Patients may experience increase in morbidity and mortality due to escalated doses of benzodiazepines.
- 4. There are likely a subset of patients that respond poorly to benzodiazepines, therefore requiring alternative mechanisms to treat AWS.
- 5. Phenobarbital (PB) has some theoretical benefits over benzodiazepines alone from a mechanistic perspective.
a. Chronic alcohol use leads to down regulation of GABA-A receptors and up-regulation of NMDA
receptors.
b. Abrupt withdrawal of alcohol use leads to greater NMDA receptor mediated excitatory activity,
which may be inhibited more effectively with phenobarbital rather than benzodiazepines.
Pharmacology
| Category | Details |
|---|---|
| Dose | Prior to benzodiazepines • 5-10 mg/kg over 30 minutes ◦ Can split up into multiple doses if concerned about respiratory depression |
| After receiving benzodiazepines • 130-260 mg PRN Q30 minutes to clinical effect (Max ~10-15 mg/kg) | |
| Mechanism of Action | Bind to the GABA receptor at a different binding site than BZDs, increasing the time the GABA-mediated chloride channels remain open • Inhibitor of excitatory AMPA glutamates receptors |
| Formulations | IV/IM/PO |
| PK/PD | Onset: IV ~5 minutes Duration: 6-12 hours Half-life: 80-120 hours Renal Excretions: 21% Therapeutic Blood levels: 15-40 ug/mL |
| Adverse Effects | Hypotension, respiratory depression, ataxia, lethargy |
| Drug Interactions and Warnings | Warning with loading doses in patients that are hypotensive and received large doses of benzodiazepines |
| Compatibility | Compatible with NS, D5W, and LR |
Evidence
| Author, year | Design/ sample size | Intervention & Comparison | Outcome |
|---|---|---|---|
| Ibarra, 2019 | Retrospective observational/ n=78 | Lorazepam protocol only (LZP) PB x 1 + LZP protocol (PB+LZP) | No difference in daily lorazepam requirements or hospital LOS PB+LZP group had ↑ pts d/c within 72 hrs No patient in PB group experienced intubation or hypotension |
| Nisavic, 2019 | Retrospective observational/ n=562 | BZD only fixed dosing PB- Based Protocol (IM load + PO taper) | No difference in AWS-related seizures, ICU admission, over-sedation, LOS, and hallucinations ↑ Delirium in BZD group In BZD→PB crossover pts, PB led to rapid improvement of BZD resistant AWS symptoms |
| Nelson, 2019 | Pre-post observational/ n=300 | IV diazepam alone (DZP) IV LZP + IV PB (LZP + PB) IV PB alone (PB) | No difference in ICU admission, ICU LOS, and need for intubation. PB associated with ↑ ED LOS but ↓ BZD requirements |
| Tidwell, 2019 | Pre-post observational/ n=120 | BZD only CIWA- Protocol PB Taper +/- Benzo PRN | PB ↓ ICU+ Hospital LOS PB ↓ total lorazepam requirements PB had less patient intubated |
| Sullivan, 2018 | Retrospective observational/ n=209 | BZD only CIWA- Protocol PB + BZD CIWA Protocol | No difference in ICU admission, intubation, hypotension, ED LOS, CIWA score at ED discharge PB group had ↓ hospital LOS and Max CIWA score at 24 hrs |
| Rosenson, 2013 | RCT/ n=102 | PB 10 mg/kg IV x1 + PRN benzodiazepines Placebo + PRN benzodiazepines | PB had ↓ ICU admission PB had ↓ continuous infusion lorazepam PB had ↓ total lorazepam requirements No difference in ICU or hospital LOS |
BZD = Benzodiazepines; DZP = diazepam; ED = emergency department; ICU = Intensive care unit; LOS = length of stay; LZP = lorazepam; PB = Phenobarbital; ↓ = statistically significant decreased; ↑ = statistically significant increased.
Conclusions
References
- Phenobarbital. Micromedex [Electronic version].Greenwood Village, CO: Truven Health Analytics. Retrieved September 28, 2019, from http://www.micromedexsolutions.com/
- Sullivan SM et al. Am J Emerg Med. 2019 Jul;37(7):1313-1316.
- Rosenson J et al. J Emerg Med 2013;44:592-8 [e2].
- Nisavic M et al. Psychosomatics. 2019 Sep - Oct;60(5):458-
- Ibarra F Jr et al. Am J Emerg Med. 2019 Jan 30. pii: S0735- 6757(19)30075-0
- Nelson AC et al. Am J Emerg Med. 2019 Apr;37(4):733-736.
- Tidwell WP et al. Am J Crit Care. 2018 Nov;27(6):454-460
Never Miss a Friday Pearl
Get Pharmacy Pearls in your inbox every Friday
Free weekly clinical pearls written for pharmacists. Practical, evidence-based, and built for bedside use.
Free forever. Unsubscribe anytime. No spam, ever.